This conversation will focus on the fascinating story of chemical innovation underlying the development of effective treatments along with their global impact. The event, moderated by Jeffrey Sturchio, will engage four luminaries in HIV/AIDS research, policy, and practice -- Gregg Alton and Norbert Bischofberger from Gilead Sciences, and Sir Richard Feachem and Paul Volberding from the University of California, San Francisco -- in a conversation about both the remarkable progress we have seen in HIV therapies and the challenges still to be met. Registration required.